Sevelamer (carbonate)

Sevelamer (carbonate)

• CAS Number: 845273-93-0
• UNSPSC Description: Sevelamer carbonate is an orally active and non-calcium-based phosphate binding agent and used for the hyperphosphatemia of chronic kidney disease (CKD)research. Sevelamer carbonate effectively lowers serum phosphorus levels hile having minimal effect on serum calcium or serum chloride levels in vivo. Sevelamer carbonate is considered as an improved, buffered form of sevelamer (HY-13995)[1][2].
• Target Antigen: Others
• Type: Reference compound
• Related Pathways: Others
• Applications: Metabolism-protein/nucleotide metabolism
• Field of Research: Metabolic Disease
• Assay Protocol: https://www.medchemexpress.com/sevelamer-carbonate.html
• Solubility: 10 mM in DMSO
• Smiles: NCC(CC(CC)CNCC(O)CNCC(C)CC(CC)CN)CC.[m].[c].[b].[a].[m H2CO3]
• References & Citations: [1]Mary M Barna, et al.Sevelamer carbonate.Ann Pharmacother. 2010 Jan;44(1):127-34.|[2]Barbara Ruggiero, et al. Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. Am J Kidney Dis|[3]Susan C Schiavi, et al. Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol. 2012 Oct;23(10):1691-700.|[4]Yongsheng Yang, et al. Evaluation of the In Vitro Efficacy of Sevelamer Hydrochloride and Sevelamer Carbonate. J Pharm Sci. 2016 Feb;105(2):864-875|[5]Bennis Y, et al. The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Toxins (Basel). 2019 May 17;11(5):279.
• Shipping Conditions: Room Temperature
• Clinical Information: Launched